Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nucleonics Inc.

This article was originally published in Start Up

Executive Summary

Nucleonics Inc. has turned to plasmid DNA delivery technology as an answer to the siRNA delivery challenge. The company believes this approach could be an effective mechanism for selectively targeting viruses, and offers significant advantages over other methods for generating a gene silencing response in targeted cells

You may also be interested in...

RNAi Start-Ups Continue Seeking, Attracting Support: Private Investors Like Nucleonics' Focus

Nucleonics, like other companies competing in the new field of RNAi, started out with big ambitions. Even before its Series A financing ran out, the company decided to focus on clinical goals. Nucleonics has just received a $41 million financing meant to see two drug candidates, presently still in preclinical testing, get through Phase II. Investors like its focus. Meanwhile, Alnylam still has big plans, which it's now hoping to finance through the public markets.

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing

Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.


Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts